이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma

2026년 8월 4일 업데이트: Tang-Du Hospital

Efficacy and Safety of Penpulimab Combined With Chemotherapy as Neoadjuvant Therapy in Patients With Locally Advanced Hypopharyngeal Carcinoma

This is a prospective, single-arm, phase II clinical study aimed to evaluate the efficacy and safety of penpulimab combined with chemotherapy in the treatment of locally advanced hypopharyngeal carcinoma.

연구 개요

상세 설명

This is a prospective, single-arm, phase II clinical study aiming to evaluate the efficacy and safety of penpulimab combined with chemotherapy in patients with locally advanced hypopharyngeal carcinoma. The study intends to explore whether penpulimab combined with chemotherapy can improve the pathological complete response rate (pCR) and overall survival (OS) compared with historical data. Approximately 15 eligible patients will be recruited at Tangdu Hospital. Enrollment is expected to be completed within one year, and all enrolled subjects meeting the inclusion criteria will be followed up for 5 years.

연구 유형

중재적

등록 (추정된)

15

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Shanxi
      • Xi’an, Shanxi, 중국, 710038
        • Tangdu Hospital, Air Force Medical University, Xi'an 710038, Shaanxi Province, China
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • 1. Aged 18 to 80 years old (inclusive of 18 and 80 years), of either gender. 2.Histopathologically or cytologically confirmed, and diagnosed as resectable locally advanced hypopharyngeal carcinomaby (LAHC ) MRI imaging.3.At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.4. Male subjects are eligible if they agree to comply with the following standards during treatment and for at least 180 days after the last cycle of chemotherapy:a) Prohibition of sperm donation;AND• Abstain from heterosexual intercourse as a usual and preferred lifestyle (long-term and persistent abstinence) and agree to maintain abstinence;OR• Agree to use contraceptive measures unless confirmed as azoospermic (vasectomy or secondary to medical reasons, see Appendix 5), with details as follows:→ Use a male condom during penile-vaginal intercourse with a reproductive-aged female partner who is not currently pregnant, and the partner uses an additional contraceptive method.Note: Males whose partners are pregnant or breastfeeding must agree to either maintain abstinence from penile-vaginal intercourse at all times or use a male condom for every penile-vaginal penetration.b) Male subjects must also agree to use a male condom during any activity that allows ejaculation with others of any gender.c) Contraceptive methods used by males must comply with regulations regarding contraception in clinical research participation.5.Female subjects are eligible if they are not pregnant or breastfeeding, and meet at least one of the following conditions:(1) Not a woman of childbearing potential (WOCBP);OR(2) If a WOCBP, use a highly effective contraceptive method (annual failure rate <1%) with low user dependence, or abstain from heterosexual intercourse as a preferred and regular lifestyle (long-term and persistent abstinence) during the intervention period and for at least 210 days after the last cycle of chemotherapy, and agree not to donate ova (eggs, oocytes) to others or freeze/store ova for personal reproductive purposes during this period. Investigators shall evaluate the likelihood of contraceptive method failure (i.e., non-compliance, recent initiation) relative to the first administration of study treatment.a) WOCBP must have a negative result on a highly sensitive urine or serum pregnancy test (urine or serum test selected per regulatory requirements) within 24 hours (urine) or 72 hours (serum) before the first administration of study treatment to be enrolled.Note: If the interval between the screening pregnancy test and the first administration of study intervention exceeds 24 hours (urine) or 72 hours (serum), a repeat pregnancy test (urine or serum) must be performed, and the result must be negative for the subject to start receiving study medication.b) If a urine test is inconclusive (e.g., unclear result), a serum pregnancy test is required. In such cases, subjects with a positive serum pregnancy test result must be excluded.c) Investigators are responsible for reviewing medical history, menstrual history, and recent sexual activity to reduce the risk of enrolling women with undetected early pregnancy.d) Contraceptive methods used by females must comply with regulations regarding contraception in clinical research participation;6.Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2 within 3 days before the first administration of study intervention.7.Evidence of extranodal extension (ENE) in lymph nodes (confirmed by MRI, CT, or pathology).8.Voluntarily sign the written informed consent form for the study.9.Expected survival time ≥6 months.10.Adequate organ function as indicated by screening laboratory test results.a) Hematological parameters:White blood cell (WBC) count ≥4 × 10⁹/L;Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L;Platelet count ≥100 × 10⁹/L;Hemoglobin (Hb) ≥90 g/L;b) Renal function:Serum creatinine ≤1.5 × upper limit of normal (ULN), or creatinine clearance (CrCl) >60 mL/min (calculated using the Cockcroft-Gault formula):Female: CrCl = [(140 - age) × body weight (kg) × 0.85] / (72 × Scr [mg/dL])Male: CrCl = [(140 - age) × body weight (kg) × 1.00] / (72 × Scr [mg/dL])c) Hepatic function:Serum total bilirubin ≤1.5 × ULN;Aspartate aminotransferase (AST) ≤2.5 × ULN;Alanine aminotransferase (ALT) ≤2.5 × ULN;d) Coagulation function:International Normalized Ratio (INR) ≤1.5;Prothrombin time (PT) or activated partial thromboplastin time (APTT) ≤1.5 × ULN.11.Good compliance and willingness to cooperate with follow-up procedures.

Exclusion Criteria:

- 1.Prior systemic therapy for advanced (metastatic) or unresectable (locally advanced) hypopharyngeal carcinoma, except for permitted neoadjuvant/adjuvant therapy. Neoadjuvant/adjuvant therapy must have been completed at least 6 months before the diagnosis of advanced and/or unresectable disease. Subjects who received prior neoadjuvant/adjuvant therapy and had R2 pathology after tumor resection are excluded.

2.Active autoimmune disease requiring systemic therapy (i.e., disease-modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years. Replacement therapies (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) are not considered systemic therapy and are permitted.3.Major surgery prior to the initiation of study intervention with inadequate recovery from surgery and/or surgical complications.4.Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or drugs targeting other stimulatory or co-inhibitory T-cell receptors (e.g., CTLA-4, OX-40, CD137).5.Prior treatment with EGFR-targeted agents.6.Anti-tumor therapy for advanced tonsillar cancer, including investigational drugs, within 4 weeks before enrollment.7.Unresolved adverse events (AEs) from prior anti-cancer therapy (i.e., AEs > Grade 1 or baseline). Subjects with neuropathy ≤ Grade 2 may be eligible based on investigator assessment.8.Radiotherapy within 2 weeks before the start of investigational treatment. Subjects must have recovered from all radiotherapy-related toxicities, be free of corticosteroid use, and have no history of radiation pneumonitis. A 1-week washout period is permitted for palliative radiotherapy (≤2 weeks of radiotherapy) for non-central nervous system (CNS) disease (if deemed safe by the investigator). A 2-week washout period is required for longer radiotherapy courses (>2 weeks).9.Administration of live vaccines within 30 days before the first dose of study drug.Note: Live vaccines include, but are not limited to: measles, mumps, rubella, varicella/zoster (chickenpox), yellow fever, rabies, bacillus Calmette-Guérin (BCG), and typhoid vaccines. Seasonal influenza vaccines administered by injection are generally inactivated virus vaccines and are permitted; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not permitted.10.Current or prior participation in a study of an investigational drug, or use of an investigational device within 4 weeks before the first dose of study drug.Note: Subjects who have entered the follow-up phase of an investigational study are eligible to participate in this study if at least 4 weeks have passed since the last dose of the prior investigational drug.11.Diagnosis of immunodeficiency or receipt of long-term systemic corticosteroid therapy (dose exceeding 10 mg prednisone equivalent per day) or any form of immunosuppressive therapy within 7 days before the first dose of study drug.12.History of another invasive malignancy that is progressive or required active treatment within the past 3 years.Note: Subjects with a history of skin basal cell carcinoma, skin squamous cell carcinoma, or carcinoma in situ (e.g., ductal carcinoma in situ of the breast, cervical carcinoma in situ) who have received potentially curative treatment are not excluded.13.Severe hypersensitivity reaction (> Grade 3) to toripalimab, nimotuzumab, albumin-bound paclitaxel, carboplatin, and/or any of their excipients.14.History of (non-infectious) pneumonitis requiring corticosteroid therapy, or current pneumonitis.15.Active infection requiring systemic therapy.16.Known history of human immunodeficiency virus (HIV) infection.17.Known active tuberculosis (TB; Mycobacterium tuberculosis).18.Severe, poorly controlled concurrent diseases (e.g., heart failure, diabetes mellitus, hypertension, liver failure, renal failure, thyroid disease, psychiatric illness, etc.).19.Major surgery within 30 days before the first dose of investigational drug or planned surgery during the study period.20.Inappropriate for study participation as assessed by the investigator.21.Unwillingness to participate in the study or inability to sign the informed consent form.22.Known history or any evidence of central nervous system (CNS) metastases and/or carcinomatous meningitis as assessed by the study site investigator.23.History or evidence of disease, treatment, or abnormal laboratory values that may interfere with trial results, prevent full participation in the study (e.g., hearing impairment), or that the investigator believes would not be in the subject's best interest to participate.24.Known psychiatric illness or substance abuse disorder that would interfere with the subject's ability to comply with study requirements.25.History of allogeneic tissue/solid organ transplantation.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: An Exploratory Study of Neoadjuvant Vibecortamab Combined with Putilimab in Locally Advanced Larynge
Finotonlimab 200 mg, intravenous infusion on Day 1, once every 3 weeks for 2 cycles; nab-paclitaxel 260 mg/m², intravenous infusion on Day 1, once every 3 weeks for 2-4 cycles. The dose of carboplatin will be calculated using the Calvert formula (Dose = target AUC × [GFR + 25]), administered via intravenous infusion on Day 1 once every 3 weeks for 2-4 cycles. Infusion-related reactions shall be closely monitored. All patients will receive 2-4 cycles of neoadjuvant combination chemotherapy, and endoscopy and radiological evaluation will be performed at approximately Day 42.
치료 요법: Nab-paclitaxel은 260mg/m²의 용량으로 정맥 내 주입하여 투여되었으며, D1, Q3W, 2-4주기 동안
치료 요법: Carboplatin 용량은 Calvert 공식(용량 = 목표 AUC × [GFR + 25])을 사용하여 계산되었으며, d1, IV, Q3W, 2-4주기 동안 투여
다른 이름들:
  • 카보플라틴 (신보조)
  • 카보플라틴 (AUC 6)
  • 카보플라틴 (AUC 5)
Finotonlimab was administered by intravenous infusion at a dose of 200 mg,d1, Q3W,for 2-4 cycles Other Name:

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Major pathological response rate (MPR)
기간: [Time Frame: Within 1-2 week after radical surgery (performed 2-3 weeks after the completion of 2 cycles of neoadjuvant treatment)]
residual tumor in the primary lesion < 10% (pathological assessment).
[Time Frame: Within 1-2 week after radical surgery (performed 2-3 weeks after the completion of 2 cycles of neoadjuvant treatment)]

2차 결과 측정

결과 측정
측정값 설명
기간
Pathological complete response rate (pCR)
기간: [Time Frame: Within 1-2 week after radical surgery (same time point as MPR assessment)]
no residual tumor cells in the primary lesion and lymph nodes after surgery (pathological assessment).
[Time Frame: Within 1-2 week after radical surgery (same time point as MPR assessment)]
Surgical resection margin (first margin and second margin)
기간: [Time Frame: Within 1-2 week after radical surgery (performed 2-3 weeks after the completion of 2 cycles of neoadjuvant treatment)]

First margin: tumor margin before neoadjuvant therapy;

Second margin: tumor margin after neoadjuvant therapy (defined as Clear margin per the 2025 NCCN Guidelines: the distance from invasive tumor to the resection margin ≥ 5 mm).

[Time Frame: Within 1-2 week after radical surgery (performed 2-3 weeks after the completion of 2 cycles of neoadjuvant treatment)]
Radiological response rate
기간: [Time Frame: After the completion of 2 cycles of neoadjuvant treatment (each cycle is 21 days)]
evaluated by contrast-enhanced CT/MRI before and after treatment (per RECIST 1.1 criteria: complete response [CR]/partial response [PR]/stable disease [SD]/progressive disease [PD]).
[Time Frame: After the completion of 2 cycles of neoadjuvant treatment (each cycle is 21 days)]
Functional preservation rate
기간: [Time Frame: functional assessment: before surgery,and 1 month, 6 months, and 1 year after surgery or Concurrent chemoradiotherapy]
Functional preservation rate was defined as the proportion of patients with normal phonation and swallowing function: before surgery, and 1 month, 6 months, and 1 year after surgery or radiotherapy (evaluated via video laryngoscopy + scale assessment + voice analysis)
[Time Frame: functional assessment: before surgery,and 1 month, 6 months, and 1 year after surgery or Concurrent chemoradiotherapy]
Disease-free survival (DFS)
기간: [Time Frame: 72 months after treatment initiation]
the time from the initiation of radical treatment to the first occurrence of disease recurrence, metastasis, second primary cancer, or death from any cause.
[Time Frame: 72 months after treatment initiation]

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: DaQing Zhao, Tangdu Hospital, Air Force Medical University (AFMU), Xi'an, China

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 8월 23일

기본 완료 (추정된)

2031년 8월 23일

연구 완료 (추정된)

2031년 8월 23일

연구 등록 날짜

최초 제출

2026년 8월 4일

QC 기준을 충족하는 최초 제출

2026년 8월 4일

처음 게시됨 (실제)

2026년 8월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 7일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 4일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다